The Nation and military readiness are impacted by the quality, safety, and availability of pharmaceutical products. The Assessing the Security and Quality of the U.S. Military Health System Pharmaceutical Supply Chain (PhaSQ) pilot study benefits the entire Nation by identifying and potentially mitigating the negative impacts of ineffective, impure, or unavailable pharmaceuticals. A lack of resilience and lack of transparency regarding quality in the supply chain, and the reliance on other countries to manufacture crucial drugs, are known national security risks. This project will be completed via four lines of effort. The first line of effort compares the essential medicines lists between the US Department of Defense (DoD), Food and Drug Administration, Department of Health and Human Services, and World Health Organization. The second line of effort synthesizes recommendations made to the DoD by other government agencies to strengthen its pharmaceutical supply chain. The third line of effort assesses the acceptability of a proposed “red, yellow, green” scoring tool for drug quality, which will include participants from the DoD, other federal agencies, and members from the private sector of the US healthcare system. The last line of effort, undertaken in partnership with Valisure, LLC, evaluates 42 drug products for quality and safety. To date we have completed the first two of our four lines of effort. All lines of effort are expected to be completed in 2026. Findings from this study are anticipated to inform decision making regarding sourcing and distribution of high-quality essential drug products.